Search results
Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan
Pharmaceutical Technology· 6 days agoEZHARMIA is the first dual EZH1 and EZH2 inhibitor to receive approval for this indication. The...
EZHARMIA is the first dual EZH1 and EZH2 inhibitor to receive approval for this indication. The...